Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Strategy and Its Executives Face Class Action Lawsuit Accused of Making False Statements About Bitcoin Investment Strategy

Strategy and Its Executives Face Class Action Lawsuit Accused of Making False Statements About Bitcoin Investment Strategy

ChaincatcherChaincatcher2025/05/19 13:07
Show original

According to ChainCatcher, documents submitted to the US SEC by Strategy reveal that on May 16, 2025, a class action lawsuit was filed in the Federal Court of the Eastern District of Virginia against Strategy and its executives, including Michael J. Saylor, Phong Le, and Andrew Kang. The plaintiffs accuse the defendants of violating Sections 10(b) and 20(a) of the Securities Exchange Act and its related rules during the period from April 30, 2024, to April 4, 2025, specifically including:

Making false and/or misleading statements about the expected profitability of the company's Bitcoin investment strategy;

Failing to disclose risks associated with Bitcoin volatility and potential significant losses due to Accounting Standards Update (ASU 2023-08).

The lawsuit seeks compensation for investors for losses that may have been incurred due to the aforementioned actions.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks